Skip to main content

By: University of Cincinnati Cancer Center

Clinical Trial Highlight: New Beat AML Sub-Study Examines the Efficacy of Using a Lower-Dose of Common Treatment in Patients with Newly Diagnosed AML

The University of Cincinnati Cancer Center Clinical Trials Office recently opened a trial to compare a lower-than-standard dosage of a widely used treatment in newly diagnosed acute myeloid leukemia (AML) patients. This clinical trial is designed to evaluate the efficacy this dosage and treatment schedule of Venetoclax plus Azacitidine may have for newly diagnosed AML patients.

  • Tags:
  • Cancer Research,
  • Clinical Trial,
Full story About: Clinical Trial Highlight: New Beat AML Sub-Study Examines the Efficacy of Using a Lower-Dose of Common Treatment in Patients with Newly Diagnosed AML

By: University of Cincinnati Cancer Center

Tammy Holm, MD, PhD Awarded ThyCa Award

  • Tags:
  • awards,
  • Endocrine,
  • Thyroid Cancer,
Full story About: Tammy Holm, MD, PhD Awarded ThyCa Award

By: University of Cincinnati Cancer Center

Survivorship Grant Awardees Spotlight - May 2023

  • Tags:
  • Cancer Center,
  • Grants,
  • Survivorship,
Full story About: Survivorship Grant Awardees Spotlight - May 2023

By: Karen Bankston, PhD, MSN

Cancer Care in the Black Community

Black people have the highest death rate and shortest survival of any racial/ethnic group in the United States for most cancers. An underlying source of health disparities among people of color is structural racism, which is defined as discrimination perpetuated through interconnected institutions and reinforced through culture, history, ideology, and sanctioned practices.

  • Tags:
  • Community Outreach,
  • DEI,
Full story About: Cancer Care in the Black Community

Contact Us

University of Cincinnati
Cancer Center

231 Albert Sabin Way, Suite 2005
Cincinnati, OH 45267
Phone: 513-558-2177
Fax: 513-558-2666